Biorepositories for NCI-Sponsored Cancer Clinical Trials

Logistics


Funding

Due to the considerable value of biospecimens annotated with clinical outcome data, funding must be available and committed to the proposal before biospecimens can be distributed. If funding is not available at the time the proposal is approved, peer reviewed funding may be sought, and the Cooperative Group can allow an appropriate time period for a grant award before its approval expires.

Return to Top

Material Use Agreement and Intellectual Property Rights

Prior to release of specimens, a signed MUA with the Cooperative Group is required. Negotiation of intellectual property rights resides with the Cooperative Group or the Cooperative Group grantee institution.

Return to Top

IRB

Review by the IRB at the site where the research will be conducted is required prior to release of Cooperative Group materials.

Return to Top

Statistical Analyses

Correlative analysis of assay results with the clinical data will generally be conducted by the statistical center of the lead Cooperative Group or their designee. Exceptions will be made when highly complex analyses are required, e.g., in cases of genetic or epigenetic profiling.

Return to Top

Authorship and Publications

Negotiation of authorship and publications pertaining to use of CGB biospecimens resides with the Cooperative Group or the Cooperative Group grantee institution.

Return to Top

Communication with Biorepository

Direct communication between the Biorepositories and the recipient is strongly encouraged. This communication can be either through email or telephone. Appropriate contact information for each Cooperative Group Banks is found on the Contacts page.

Return to Top